<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Impact of addition of immune checkpoint inhibitors to neoadjuvant chemotherapy in triple-negative breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Impact of addition of immune checkpoint inhibitors to neoadjuvant chemotherapy in triple-negative breast cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Impact of addition of immune checkpoint inhibitors to neoadjuvant chemotherapy in triple-negative breast cancer</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup> <colgroup span="5" width="8%"></colgroup> <colgroup span="1" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1 divider_bottom" rowspan="2"> <p>Study [reference]</p> Immunotherapy agent (target)</td> <td class="subtitle1 divider_bottom" rowspan="2">Chemotherapy regimen</td> <td class="subtitle1 divider_bottom" rowspan="2">Sub-group</td> <td class="subtitle1" colspan="2">Immunotherapy</td> <td class="subtitle1" colspan="2">Control (placebo)</td> <td class="subtitle1 divider_bottom" rowspan="2">EFS results (IT versus control)</td> </tr> <tr class="divider_bottom"> <td class="subtitle2">Number</td> <td class="subtitle2">pCR* (%)</td> <td class="subtitle2">Number</td> <td class="subtitle2">pCR* (%)</td> </tr> <tr> <td class="divider_bottom" rowspan="3"> <p><strong>KEYNOTE-522<sup>[1,2]</sup></strong></p> <strong>Pembrolizumab (PD-1)</strong></td> <td class="divider_bottom" rowspan="3">Weekly paclitaxel with carboplatin (weekly or every 3 weeks) for 12 weeks followed by doxorubicin or epirubicin and cyclophosphamide for 4 cycles</td> <td>All</td> <td>784</td> <td>65<sup>¶</sup></td> <td>390</td> <td>51<sup>¶</sup></td> <td class="divider_bottom" rowspan="3">At median follow-up of 39 months, 3-year EFS 84 versus 77% (HR 0.63, 95% CI 0.48-0.82)</td> </tr> <tr> <td>PD-L1+</td> <td>656</td> <td>69</td> <td>317</td> <td>55</td> </tr> <tr class="divider_bottom"> <td>PD-L1–</td> <td>127</td> <td>45</td> <td>69</td> <td>30</td> </tr> <tr> <td class="divider_bottom" rowspan="3"> <p><strong>Impassion031<sup>[3]</sup></strong></p> <strong>Atezolizumab (PD-L1)</strong></td> <td class="divider_bottom" rowspan="3">Weekly nabpaclitaxel for 12 weeks followed by doxorubicin and cyclophosphamide for 4 cycles</td> <td>All</td> <td>165</td> <td>58</td> <td>168</td> <td>41</td> <td class="divider_bottom" rowspan="3">At approximately 20 months' median follow-up, EFS not reached (HR 0.76, 95% CI 0.4-1.44)</td> </tr> <tr> <td>PD-L1+</td> <td>77</td> <td>69</td> <td>75</td> <td>49</td> </tr> <tr class="divider_bottom"> <td>PD-L1–</td> <td>88</td> <td>48</td> <td>93</td> <td>34</td> </tr> <tr> <td class="divider_bottom" rowspan="3"> <p><strong>NeoTRIPaPDL1<sup>[4]</sup></strong></p> <strong>Atezolizumab (PD-L1)</strong></td> <td class="divider_bottom" rowspan="3">Nabpaclitaxel and carboplatin days 1 and 8 every 21 days for 8 cycles</td> <td>All</td> <td>138</td> <td>49</td> <td>142</td> <td>44</td> <td class="divider_bottom" rowspan="3">Not reported</td> </tr> <tr> <td>PD-L1+</td> <td>79</td> <td>60</td> <td>77</td> <td>52</td> </tr> <tr class="divider_bottom"> <td>PD-L1–</td> <td>59</td> <td>34</td> <td>65</td> <td>35</td> </tr> <tr> <td rowspan="4"> <p><strong>GeparNUEVO<sup>[5,6]</sup></strong></p> <strong>Durvalumab (PD-L1)</strong></td> <td rowspan="4">Weekly nabpaclitaxel for 12 weeks followed epirubicin and cyclophosphamide for 4 cycles</td> <td>All</td> <td>88</td> <td>53</td> <td>86</td> <td>44</td> <td rowspan="4">At median follow-up of 42 months, 3-year iDFS 85 versus 77% (HR 0.54, 95% CI 0.27-1.09)</td> </tr> <tr> <td>PD-L1+</td> <td>69</td> <td>58</td> <td>69</td> <td>51</td> </tr> <tr> <td>PD-L1–</td> <td>11</td> <td>44</td> <td>9</td> <td>18</td> </tr> <tr> <td>Window<sup>Δ</sup></td> <td>59</td> <td>61</td> <td>58</td> <td>41</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>IT: immunotherapy;
    pCR: pathologic complete response;
    PD-1: programmed cell death protein 1;
    EFS: event-free survival;
    PD-L1: programmed cell death ligand 1;
    HR: hazard ratio;
    iDFS: invasive disease-free survival.</p>
<p>* pCR: ypT0/isN0.</p>
<p>¶ The pCR values listed for KEYNOTE-522 comes from the initial presentation of results for the first 602 patients. When results for all patients were available, final pCR rates were 63 and 56% for pembrolizumab and placebo, respectively.</p>
    
    Δ The first 117 patients treated on GeparNeuvo received a single dose of either durvalumab or placebo two weeks before starting neoadjuvant chemotherapy with the same agent; this was omitted after the study's independent data monitoring committee expressed concern about the delay in the start of chemotherapy; another 57 patients were subsequently treated without this "window" treatment.</div><div class="graphic_reference">References:
    <ol>
<li>Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382:810.</li>
<li>Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022; 386:556.</li>
<li>Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial. Lancet 2020; 396:1090.</li>
<li>Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol 2022; 33:534.</li>
<li>Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 2019; 30:1279.</li>
<li>Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol 2022; 33:1149.</li>
</ol></div><div id="graphicVersion">Graphic 129974 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
